Association of Immunogenicity With the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Biosimilar, SB11, and Reference Product
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial
JAMA Ophthalmol 2022 Dec 15;[EPub Ahead of Print], NM Bressler, T Kim, I Oh, P Russo, MY Kim, SJ WooFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.